Patent ID: 8920800

Claim:
A method of treating a human having a cancer, the method comprising: reducing the fibroblast growth factor-2 (FGF-2) plasma concentration of the human below 4 pg/ml for at least one week by administering to the human a soluble fibroblast growth factor receptor 1 (FGFR1) fusion protein at a dose of at least about 2 mg/kg body weight, wherein the soluble FGFR1 fusion protein comprises an FGFR1 extracellular domain linked to a Fc polypeptide, and wherein the human has a FGF-2 plasma concentration of at least 6 pg/ml prior to administration of the soluble FGFR1 fusion protein; and wherein the method further comprises administering at least one chemotherapeutic agent.